This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-GD2 IgG to GM-CSF. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the GD2 as well as the biological activity of GM-CSF. This antibody-cytokine fusion protein retains the ability to induce ADCC and CDC activity. The fusion of GM-CSF to the antibody increased its cytotoxicity against NMB7 neuroblastoma cells by granulocytes isolated from neuroblastoma patients, and increased ADCC-mediated by mononuclear cells from the same patients, in comparison with ch14.18 alone. This immunocytokine was designed for treating GD2-positive tumors.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
NAB-770-sdAb | Recombinant Anti-Human GD2 VHH Single Domain Antibody | Neut, ChiP, IP, FUNC | Llama VHH |
There are currently no Customer reviews or questions for ACFP-SH021. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.